Skip to content
OpenCapital
Get started

Pfizer PFE Tukysa — Finite-lived intangible assets, period increase

Other product segments

Padcev
$600M—

Similar metrics at other companies

Biogen logo
BIIBTysabri Product — Finite Lived Intangible Assets Net
$1.8B-9.1%
United Therapeutics logo
UTHRTrevyent — Indefinite-lived intangible assets (excluding goodwill)
$107.3M—
United Therapeutics logo
UTHRTrevyent — Intangible asset impairment charges
$107.3M—
Biogen logo
BIIBTecfidera — Finite Lived Intangible Assets Net
$36.1M-49.2%
Incyte logo
INCYtafasitamab — Upfront and immediate milestone payment to be received under license agreement
$82.5M0.0%
Agilent Technologies logo
ALife Sciences and Applied Markets — Additions and adjustments to other intangibles
$186M—

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's tukysa — finite-lived intangible assets, period increase.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's tukysa — finite-lived intangible assets, period increase?
Pfizer (PFE) reported tukysa — finite-lived intangible assets, period increase of $580M in Q1 2026.
What does tukysa — finite-lived intangible assets, period increase mean?
The total value of new finite-lived intangible assets added to the Tukysa product line during the period.
How do you interpret tukysa — finite-lived intangible assets, period increase?
An increase indicates active investment in the commercialization or technological development of the product, suggesting management's commitment to its long-term revenue potential.
How does tukysa — finite-lived intangible assets, period increase compare across companies?
Similar to capitalized development costs or acquired product rights reported by peers in the oncology and specialty pharmaceutical sectors.